使用他非诺喹治疗一名患有复发性巴贝斯虫病的患者，该患者具有对阿奇霉素和阿托伐醌耐药的临床及分子证据。

Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.

作者信息

Marcos Luis A, Leung Annie, Kirkman Laura, Wormser Gary P

机构信息

Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Stony Brook University, USA.

Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.

出版信息

IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.

DOI:10.1016/j.idcr.2022.e01460

PMID:35242564

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8885462/

Abstract

Tafenoquine is a highly effective treatment for infections in animal models. An immunocompromised patient infected by a strain of that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.

摘要

他非诺喹是动物模型感染的高效治疗药物。一名免疫功能低下的患者感染了一种对阿奇霉素和阿托伐醌至少部分耐药的巴贝斯虫菌株，接受了他非诺喹治疗。应考虑开展使用他非诺喹治疗其他巴贝斯虫病患者的系统临床研究。